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Prodrug strategy to increase oral absorption 
Prodrugs are bioreversible derivatives of drug molecules designed to overcome 
pharmaceutical, pharmacokinetic or pharmacodynamic barriers such as low oral 
absorption, lack of site specificity, insufficient chemical stability, poor solubility, 
toxicity, etc.[1] To improve oral absorption, a classic prodrug approach can be adopted to 
enhance drug lipophilicity and passive diffusion. For example, influenza neuraminidase 
inhibitor oseltamivir carboxylate is poorly absorbed from gastrointestinal tract due to 
high polarity and negative charge of the carboxyl group (Scheme 1.1). However, its ethyl 
ester prodrug, oseltamivir (trade name Tamiflu), can be effectively absorbed by passive 
diffusion and extensively metabolized to the parent drug.[2] With an absolute oral 
bioavailability of 80%, Tamiflu is the most effective orally administered drug for the 
treatment of influenza, including the currently widespread H1N1 flu. In recent years, the 
understanding of membrane transporters has promoted a novel targeted prodrug 
approach, utilizing carrier-mediated transport to increase intestinal permeability.[3] As 
examples, valacyclovir and valganciclovir, the valine ester prodrugs of poorly absorbed 
antiviral drugs acyclovir and ganciclovir, respectively, exhibit more than 50% oral 
bioavailability by hPEPT1-mediated membrane transport (Scheme 1.1).[4-7] After being 
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absorbed, prodrugs must be converted to their corresponding parent drugs to exert 
therapeutic effects. This activation process does not necessarily need to be specific; 
however, a thorough understanding of the possible activating enzymes will aid the 
rational design of successful prodrugs.  
 
Guanidino-containing drugs and prodrug strategy 
Due to the polar nature and positive charge of the guanidino functionality, it is 
hard for guanidino-containing drugs to penetrate biological membranes by passive 
diffusion. However, other transport mechanisms are employed to bring the oral 
bioavailability of some guanidino-containing drugs to a reasonable level.  For example, 
the biguanide metformin, one of the widely used oral drugs for the treatment of type 2 
diabetes, is mainly absorbed from small intestine with an oral bioavailability of 50-
60%.[8] The absorption can be associated with a combination of passive diffusion and 
carrier-mediated transport.[9-11] Another example of orally available guanidino-
containing drug is the H2-receptor antagonist famotidine, which is an organic cation 
transporter 1 (OCT1) substrate.[12] On the other hand, the low-permeability guanidino-
containing drugs cannot be given orally: the thrombin inhibitor argatroban and the 
influenza neuraminidase inhibitor zanamivir (Scheme 1.2) are dosed by intravenous 
administration[13] and inhalation[14] respectively. When oral route of administration is 
desired, the guanidino group has to be replaced in many cases, although activity may also 
be compromised. As an example, the more potent guanidino analog of oseltamivir 
carboxylate, GS 4116 (GOCarb), is not orally absorbed (Scheme 1.2).[15] Neither is its 
ethyl ester GS 4109 orally available, which suggests that the poor oral bioavailability is 
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partially attributed to the guanidino functionality. Finally, GOCarb had to be abandoned 
despite its potential as a very potent influenza neuraminidase inhibitor.  
Considering the difficulty of finding novel orally available drug candidates, 
especially anti-influenza agents, it would be beneficial to solve the permeability problem 
with a prodrug strategy. Many research groups have applied the classic prodrug approach 
to mask the charge of the guanidino group and facilitate passive diffusion, following 
activation to the parent drug.[16-19] However, this strategy has met with only limited 
success, partly due to the insufficient membrane transport and complicated activation. 
Moreover, if the drug is zwitterionic such as argatroban, zanamivir and GOCarb, all the 
charges need to be shielded, further complicating both the synthesis and the in vivo 
activation. On the other hand, prodrugs can be designed to target mucosal transporters, 
which may tolerate the guanidino functionality and other charges. Such transporters 
include organic cation transporters, amino acid transporters and oligopeptide transporters. 
 
Organic cation transporters (OCTs)  
The organic cation transporters (OCTs) facilitate the diffusion of structurally 
diverse organic cations including endogenous substrates such as monoamine 
neurotransmitters and many pharmaceutical compounds.[20, 21] The substrate and 
inhibitor specificities of OCT1, OCT2 and OCT3 overlap extensively even though the 
affinity and maximal transport rates may be different.[20, 21] OCT substrates are mostly 
organic cations including guanidino-containing compounds such as metformin and 
guanidine.[20, 22] Although OCTs are expressed in the small intestine,[20, 21, 23] their 
involvement in oral drug absorption is still not well established. Furthermore, if a 
4 
 
guanidino-containing compound is not an OCT substrate itself, it is very unlikely that a 
prodrug designed to target OCTs will have a higher oral absorption. 
 
Amino acid transporters  
The guanidino-containing amino acid L-arginine is a semiessential or 
conditionally essential amino acid in humans. It is involved in many important metabolic 
pathways, such as nitric oxide, urea, ornithine, agmatine, creatine, proline, glutamate and 
polyamine synthesis.[24] 
There are at least four different transport systems that accept arginine as a 
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Many studies suggested that amino acid transporters have potentials to serve as 
prodrug targets.[28-32] However, they are not as widely used as peptide transporters for 




Oligopeptide transporters  
The absorption and reabsorption of di- and tripeptides are mediated by human 
peptide transporter 1 (hPEPT1)
 
and human peptide transporter 2 (hPEPT2)
 
in intestinal 
and renal epithelial cells, respectively.[33-35] hPEPT1 and hPEPT2 are members of the 
Proton-coupled Oligopeptide Transporter (POT) superfamily, which contains 12 
predicted transmembrane domains with the N- and C-termini facing the cytosol.[34, 36] 
hPEPT1 is a low-affinity, high-capacity transporter; whereas hPEPT2 is a high-affinity, 
low-capacity transporter, and they share similar broad substrate specificity. In addition to 
numerous oligopeptides with different sizes and net charges, hPEPT1 and hPEPT2 can 
also accommodate peptidomimetics such as β-lactam antibiotics[37, 38] and angiotensin 
converting enzyme (ACE) inhibitors.[37, 39]  
Because of its high level of expression in the intestinal epithelium, high capacity 
and broad substrate specificity, hPEPT1 is an ideal prodrug target for oral drug delivery. 
In addition to valacyclovir and valganciclovir, researchers have attempted to improve oral 
absorption of different poorly absorbed drugs via attachment to amino acids or dipeptides 
to resemble hPEPT1 substrates, mostly through ester bonds[40-50] and amide bonds.[51-
54] Among the successful examples, most of the parent drugs are not structurally similar 
to amino acids or natural substrates of hPEPT1, and some of them are charged such as 
alendronate.[52]
 
Therefore, applying the same strategy to the positively-charged 
guanidino-containing compounds may also be promising. We chose to conjugate the 
parent compounds with the amino acid promoiety by an ester bond for more predictable 
activation by hVACVase. Compared to the classic prodrug strategy, this targeted prodrug 
approach leaves the guanidino group intact, which avoids the complicated activation 
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process and guarantees good solubility of the prodrug. Also, the activation does not 
involve toxicity issues because the only activation byproduct is an amino acid. 
 
Human valacyclovirase (hVACVase) as prodrug-activating enzyme 
For a prodrug to be successful, it must be metabolized to the active parent drug in 
vivo. In 1995, Burnette[55] et al purified and characterized a 29-kDa enzyme from rat 
liver which activates L-alanine, L-methionine, L-leucine and L-valine ester prodrugs of 
acyclovir. Although this conversion can be catalyzed either chemically or by other 
esterases or proteases, the novel enzyme which was named valacyclovirase (VACVase) 
was believed to play a major role in the activation of valacyclovir, the L-valine ester 
prodrug of acyclovir. In contrast to α-amino acid esters of acyclovir, esters without a free 
α-amino group, such as valeryl, 2, 3-dimethylbutyryl, and N-formyl-L-valyl esters of 
acyclovir, as well as p-nitrophenyl acetate and p-nitrophenyl N-tert-butoxycarbonyl-L-
alaninate are not substrates for VACVase.  In addition, neither typical peptidase nor 
arylamidase activity was detected with di- or tripeptides and aminoacyl-β-
naphthylamides. VACVase is expressed in rat liver, where it is most abundant, as well as 
kidney, lung, stomach, heart, brain and small intestine.  
In 2003, our lab identified one of the major enzymes activating valacyclovir in 
human from Caco-2 cells,[56] and both the precursor protein with a leader sequence of 
20 amino acid residues[56] and the mature form (residues 21–274)[57] were 
overexpressed in Escherichia coli and purified. This human valacyclovirase (hVACVase) 
enzyme was suggested to be the human homologue of rat VACVase, and was previously 
cloned from breast cancer tissue.[58] hVACVase is widely expressed in a variety of 
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human tissues with highest levels in liver and kidney.[58] It can efficiently metabolize 
many amino acid ester prodrugs of nucleoside analogues such as floxuridine, 
gemcitabine, acyclovir, ganciclovir, zidovudine and 2-bromo-5,6-dichloro-1-(β-D-
ribofuranosyl)benzimidazole (BDCRB) and seems to prefer amino acids with neutral side 
chains (valine, phenylalanine and proline) over charged ones (aspartic acid and 
lysine).[59] In a study of 12 different α-amino acid esters (mostly benzyl esters), 
hVACVase can accommodate all of them except L-Asn p-nitrobenzyl ester and L-Asp 
benzyl ester.[57] β-Amino acid esters, however, exhibited about 3 orders of magnitude 
lower activity than corresponding α-amino acid esters. Moreover, when the α-amino 
group was blocked or substituted by other functional groups (α-hydroxyl or hydrogen), 
the activity was lost. hVACVase did not exhibit significant hydrolytic activity towards 
common esterase substrates p-nitrophenyl acetate and p-nitrophenyl butyrate or amino 
acid and dipeptide amides of p-nitroanilide such as Lys-p-NA, Leu-p-NA, Pro-p-NA, 
Phe-p-NA, Val-p-NA and Gly-Pro-p-NA. hVACVase activity can be inhibited by serine 
hydrolase inhibitors DFP and AEBSF as well as a free thiol group modifier, PCMB. 
Taken together, the substrate specificity of hVACVase was in accordance with rat 
VACVase and all the studies suggested that hVACVase was a specific α-amino acid ester 
hydrolyzing enzyme. 
Via site-directed mutagenesis, it was confirmed that hVACVase was a serine 
hydrolase with a catalytic triad S122-H255-D227. The crystal structure of hVACVase 
binding to a product analogue revealed that the negatively charged side chain of the D123 
residue formed an electrostatic interaction with the α-amino group of the product 
analogue, explaining the importance of the free amino group in the substrate structure. 
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Because D123 is adjacent to the catalytic serine, the free amino group in the substrate 
must be close to the carbonyl carbon, which may be the reason why hVACVase is not 
very active hydrolyzing β-amino acid esters. hVACVase contains a large open leaving 
group-accommodating groove, which is consistent with the broad specificity of the 
leaving groups we tested so far, and indicates that hVACVase may be an ideal target for 
prodrug activation. Also the negative electrostatic potential in the groove suggests that 
hVACVase may prefer positively charged leaving groups such as guanidino-containing 
drugs. 
 
hVACVase-catalyzed reaction mechanism and the effect of leaving groups 
The proposed mechanism of hVACVase was shown in Scheme 1.3. With the help 
of H255, the catalytic serine attacks the carbonyl carbon of substrate and forms the first 
tetrahedral intermediate. Then the leaving group is released from the enzyme and the 
amino acid will be covalently connected to the catalytic serine. Afterwards, a water 
molecule serves as a nucleophile, and through another tetrahedral intermediate, the 
enzyme is regenerated and the final product amino acid is formed. This reaction can also 
be shown as the following scheme: 
 
 
The leaving group of the reaction will be corresponding to the drug part of the 
prodrug. In order to further explore the potential of hVACVase as a prodrug-activating 
enzyme, the effect of the leaving group on the binding and the reaction rate need to be 
understood. The rate-limiting step of hVACVase can be either acylation or deacylation, 
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with the leaving group only affecting the former. When studying the p-nitrophenyl 
acetate hydrolysis by chymotrypsin, Hartley and Kilby[60]
 
observed an initial burst of p-
nitrophenol, which reflected the much faster acylation step. However, after the reaction 
reached steady state, the reaction rate was only determined by the slower deacylation 
step. Instead of trying to observe the burst kinetics, which requires very poor substrates of 
the enzyme, we studied the kinetics of a series of amino acid analogues to find out (1) the 
rate-limiting step of hVACVase-catalyzed reaction and the effect of leaving groups on 
the reaction rate and (2) whether the leaving groups affect the binding to hVACVase. 
Based on previous studies, amino acid amides are not good substrates of hVACVase, 
which cannot be well-explained by the reaction mechanism. Since making an amino acid 
amide bond is a very promising prodrug strategy to increase oral absorption, an 
explanation on why hVACVase cannot efficiently activate amide prodrugs is crucial.  
 
Specific aims 
Amino acid ester and amide prodrugs have attracted a great deal of interest for 
improved oral bioavailability of low-permeability drugs. The purpose of this research was 
to increase the oral absorption of guanidino-containing compounds, and further 
understand the mechanism of a prodrug-activating enzyme, eventually expanding the 
application of the amino acid ester and amide prodrug approach. 
There were two specific aims of this study: 
The first specific aim was to apply a transporter- and enzyme-targeted (hPEPT1 
and hVACVase) prodrug strategy for poorly absorbed guanidino-containing molecules. A 
model parent compound and its amino acid esters were used to evaluate the feasibility of 
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this approach. The second specific aim was to investigate the effect of leaving group on 
the hVACVase-catalysed prodrug activation by comparing the kinetic data of a series of 
amino acid analogues.  
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Table 1.1. Plasma membrane transporters that accept arginine as a substrate (adopted 
from reference [25]). 
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A prodrug strategy for molecules containing the polar guanidino functionality 
 
Introduction 
Human peptide transporter 1 (hPEPT1), the oligopeptide transporter expressed in 
the apical brush border membrane of the small intestine, mediates the transport of di- and 
tripeptides and a variety of peptidomimetics across the intestinal wall.[1, 2] The broad 
substrate specificity of hPEPT1 makes it an attractive target for prodrug design. By 
conjugating to an amino acid promoiety, a low permeability drug can be recognized by 
hPEPT1 and obtain significantly higher oral absorption. As examples, valacyclovir and 
valganciclovir, the valine ester prodrugs of poorly absorbed antiviral drugs acyclovir and 
ganciclovir, respectively, exhibit more than 50% oral bioavailability by hPEPT1-
mediated membrane transport and extensive activation to their corresponding parent 
drugs.[3-6] The rapid activation of valacyclovir and valganciclovir is due to the 
cooperation of chemical hydrolysis and multiple activating enzymes. However, some 
particular esterase(s), such as a specific amino acid ester prodrug-activating enzyme we 
identified recently, human valacyclovirase (hVACVase), may be primarily responsible 
for this activation process.[7] Encouraged by the success of valacyclovir and 
valganciclovir, the amino acid ester prodrug strategy has also been applied to other 




floxuridine, [10-13] gemcitabine,[14] levovirin,[15] and cytarabine.[16]
 
Results 
suggested that the membrane permeability was increased greatly by targeting hPEPT1, 
and many of the prodrugs could be activated by hVACVase.[17]  
Frequently required for the high potency of drugs and drug candidates, the 
guanidino functionality is also an obstacle for oral absorption due to polarity and positive 
charge. Unless paracellular or active transport mechanisms exist, guanidino-containing 
drugs or drug candidates are expected to have very limited oral absorption, such as 
thrombin inhibitor argatroban as well as influenza neuraminidase inhibitors zanamivir 
and guanidine oseltamivir carboxylate (GOCarb). It is well-known that the guanidino 
group occurs in arginine-containing small peptides, which are natural substrates of 
hPEPT1 transporter. Although hPEPT1 appears to prefer neutral side chains instead of 
the charged ones,[1, 2, 18, 19] many arginine-containing small peptides still have at least  
medium affinity to hPEPT1 transporter and show evidence of transport.[18-21] Therefore, 
it will be interesting to see if other compounds with the guanidino functionality can also 
be tolerated by hPEPT1. If successful, the amino acid ester prodrug strategy may be 
applied to guanidino-containing drugs as long as an ester bond can be made through a 
hydroxyl group in the drug structure or a linker (Scheme 2.1). For this amino acid ester 
prodrug strategy, some questions that may arise are: (1) whether the guanidino 
functionality on the parent drug structure affects recognition and transport by hPEPT1, 
and (2) if the guanidino functionality plays a negative role, whether it can be 
compensated by a good amino acid promoiety so the prodrug will be transported.  
Another challenge for prodrug design is the activation process; the prodrug form 
should be retained prior to absorption and be quickly metabolized to the parent 
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compound following absorption. The classic prodrug strategy suffered from the 
unpredictable activation of the shielded guanidino functionality. The targeted prodrug 
strategy, however, circumvents this problem by leaving the guanidino group intact and at 
the same time, introducing a well-studied and relatively predictable amino acid ester 
bond. We have found that one of the primary amino acid ester prodrug-activating 
enzymes is hVACVase,[7] a serine hydrolase containing a catalytic triad S122-H255-
D227. The very specific preference for amino acid ester substrates is attributed to the 
critical residue D123 forming electrostatic interaction with the α-amino group of 
substrate. hVACVase contains a large leaving group-accommodating groove, which 
accommodates various leaving groups including nucleoside analogues acyclovir, 
ganciclovir, floxuridine, gemcitabine, zidovudine and BDCRB, as well as simple alcohols 
such as methanol, ethanol and benzyl alcohol.[7, 17, 22] In addition, the crystal structure 
of hVACVase revealed negative electrostatic potential in the groove, which may prefer a 
positively charged leaving group. Therefore, hVACVase may be a good target for 
guanidino-containing prodrugs in order to control the activation process and secure the 
quick release of parent drug in vivo.  
The specific aim of this chapter was to apply a transporter- and enzyme-targeted 
(hPEPT1 and hVACVase) prodrug strategy for guanidino-containing molecules. We have 
designed and synthesized L-valine, L-isoleucine and L-phenylalanine esters of a model 
parent compound, [3-(hydroxymethyl)phenyl]guanidine (3-HPG, Scheme 2.2). These 
promoieties were chosen based on affinity to hPEPT1 transporter and stability profiles 
learned from our previous studies of amino acid nucleoside prodrugs. D-valine ester of 3-
HPG was synthesized and used as a control to help determine the transport mechanism. 
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The different model compounds were tested for hPEPT1-mediated uptake and transport 
across HeLa/hPEPT1 and Caco-2 cells, intestinal permeability in the rats, and activation 
by hVACVase. This setup allowed us to evaluate the feasibility of the suggested strategy 




The tert-butyloxycarbonyl (Boc) protected amino acids, Boc-L-valine, Boc-L-
isoleucine, Boc-L-phenylalanine and Boc-D-valine were obtained from Calbiochem-
Novabiochem (San Diego, CA). Valacyclovir was a gift from GlaxoSmithKline, Inc. 
(Research Triangle Park, NC). High-performance liquid chromatography (HPLC) grade 
acetonitrile was obtained from Fisher Scientific (St. Louis, MO). L-Isoleucine benzyl 
ester 4-toluenesulfonate salt was obtained from Chem-Impex International, Inc. (Wood 
Dale, IL). 3-Amino benzyl alcohol, 1,3-bis(tert-butoxycarbonyl)-2-methyl-2-
thiopseudourea, N-(3-dimethylaminopropyl)-N′-ethylcarbodiimide hydrochloride 
(EDC·HCl), 4-(dimethylamino)pyridine (DMAP), trifluoroacetic acid (TFA), L-valine 
benzyl ester hydrochloride, L-phenylalanine benzyl ester hydrochloride, metoprolol, 
phenol red and all other reagents and solvents were purchased from Sigma-Aldrich Co. 
(St. Louis, MO). Cell culture reagents were obtained from Invitrogen (Carlsbad, CA), and 
cell culture supplies were obtained from Corning (Corning, NY) and Falcon (Lincoln 






NMR spectra were obtained on a Bruker AVANCE DRX500 NMR spectrometer. 
Electronspray ionization mass spectra were obtained on a Micromass LCT Time-of-
Flight mass spectrometer. The purity of all synthesized test compounds was at least 95% 
as determined by HPLC. 
[3-(Hydroxymethyl)phenyl]guanidine (3-HPG, 3). To a stirred solution of 3-amino 
benzyl alcohol (154 mg, 1.25 mmol) in 1 mL of dry tetrahydrofuran (THF), 1,3-bis(tert-
butoxycarbonyl)-2-methyl-2-thiopseudourea (145 mg, 0.5 mmol) in 1.5 mL of THF was 
added dropwise, and then temperature was increased to 50°C. After 2 hours, the reaction 
was stopped and solvents were removed. The residue was dissolved in 30 mL of 
dichloromethane and washed twice with 10 mL of brine. The organic phase was dried 
over anhydrous MgSO4 and concentrated in vacuo. The product 2 was purified by column 
chromatography (CH2Cl2 : MeOH, 60 : 1) as colorless oil. Yield: 82.4%. 119.2 mg of 2 
was dissolved in 4 mL of trifluoroacetic acid (TFA):CH2Cl2 (1:1) and stirred at room 
temperature for 5 hours. Then solvents were removed and the residue was dissolved in 
0.1% TFA, filtered and lyophilized. The raw product was further purified by semi-prep 
HPLC to give a colorless oil. Yield: 69.1%. 
1
H NMR (D2O) δ 7.40 (1H, dd, J = 7.8 Hz, 
7.8 Hz, H-5), 7.29 (1H, d, J = 7.8 Hz, H-4 or H-6), 7.22 (1H, s, H-2), 7.17 (1H, d, J = 7.8 
Hz, H-4 or H-6), 4.56 (2H, s, -CH2OH); ESI-MS:  166.0 (M+H)
+
. 
L-Isoleucine [3-[(aminoiminomethyl)amino]phenyl]methyl ester (Ile-3-HPG, 5b). 
33.1 mg of 2 (0.09 mmol), 35.6 mg of Boc-L-isoleucine (0.154 mmol) and 20.5 mg of 4-
(dimethylamino)pyridine were dissolved in 1 mL of dry CH2Cl2 and stirred in ice bath. 
30.5 mg of N-(3-dimethylaminopropyl)-N′-ethylcarbodiimide hydrochloride  (EDC·HCl, 
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0.159 mmol) was slowly added to the above solution. The reaction mixture was stirred 
overnight at room temperature until reaction was complete. The solvents were removed 
and residue was dissolved in 30 mL of CH2Cl2 and washed with 10% (w/v) citric acid, 
saturated NaHCO3 and brine. The organic phase was dried over anhydrous MgSO4 and 
concentrated in vacuo. The mixture was then chromatographed on silica gel to obtain 4b 
as colorless oil. 4b was treated with 2.2 mL of TFA:CH2Cl2 (1:1.2) under argon for 2 
hours. Solvents were removed and residue was dissolved in 0.1% TFA, filtered and 
lyophilized to give 5b as white solid.  5a, 5c and 5d were synthesized similarly. Yield of 
two steps: 70.9%. 
1
H NMR (methanol-d4) δ 7.53 (1H, dd, J=7.8 Hz, 7.8 Hz, H-5), 7.44 
(1H, d, J=7.8 Hz, H-4 or H-6), 7.38 (1H, s, H-2), 7.33 (1H, d, J=7.8 Hz, H-4 or H-6), 5.35 
(2H, m, -CH2-O-), 4.10 (1H, d, J=3.9 Hz, H-α), 2.02 (1H, m, H-β), 1.51 (1H, m, CH2- γ), 
1.35 (1H, m, CH2- γ), 0.99 (6H, m, CH3-γ, CH3-δ); ESI-MS: 279.1 (M+H)
+
. 
L-Valine [3-[(aminoiminomethyl)amino]phenyl]methyl ester (Val-3-HPG, 5a). Yield 
of two steps: 39.5%. 
1
H NMR (methanol-d4) δ 7.53 (1H, dd, J=7.8 Hz, 7.8 Hz, H-5), 7.45 
(1H, d, J=7.8 Hz, H-4 or H-6), 7.38 (1H, s, H-2), 7.33 (1H, d, J=7.8 Hz, H-4 or H-6), 5.36 




L-Phenylalnine [3-[(aminoiminomethyl)amino]phenyl]methyl ester (Phe-3-HPG, 
5c). Yield of two steps: 79.7%. 
1
H NMR (methanol-d4) δ 7.49 (1H, dd, J=7.9 Hz, 7.8 Hz, 
H-5), 7.20-7.38 (8H, m, aromatic protons), 5.27 (2H, s, -CH2-O-), 4.41 (1H, t, J=7.0 Hz, 
H-α), 3.25 (2H, m, H-β); ESI-MS: 313.1 (M+H)
+
. 
D-Valine [3-[(aminoiminomethyl)amino]phenyl]methyl ester (D-Val-3-HPG, 5d). 
Yield of two steps: 86.6%. 
1
H NMR (methanol-d4) δ 7.53 (1H, dd, J=7.8 Hz, 7.8 Hz), 
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7.44 (1H, d, J=7.8 Hz), 7.38 (1H, s), 7.32 (1H, d, J=7.8 Hz), 5.35 (2H, m), 4.02 (1H, d, 





HeLa cells (passage 17-31) and Caco-2 cells (passage 15-32) from American 
Type Culture Collection (Rockvile, MD) were routinely maintained in Dulbecco’s 
modified Eagle’s medium (DMEM) containing 10% fetal bovine serum (FBS), 1% 
nonessential amino acids, 1 mmol/L sodium pyruvate and 1% L-glutamine. Cells were 
grown in an atmosphere of 5% CO2 and 90% relative humidity at 37°C. 
 
Hydrolysis in HeLa and Caco-2 cell homogenates. 
HeLa cells or Caco-2 cells were washed with 0.15 M NaCl solution and then 
collected with 10 mM phosphate buffer (pH 7.4). The cell suspension was ultrasonicated 
in ice bath to extract enzymes. The suspension was spun at 10,000 rpm for 10 minutes at 
4°C. Supernatant was placed in a new tube. The concentration of enzyme was determined 
as protein amount with the Bio-Rad DC assay (Hercules, CA) and adjusted to 500 
µg/mL. 
Hydrolysis in cell homogenates was determined at 37 ºC. The hydrolysis reaction 
was initiated by adding 0.75 µL of test compound solution (200 mM in DMSO) to a 
reaction tube containing 749.25 µL cell homogenates. At various time points (0, 5, 10, 
30, 60 and 120 min), 100 µL of the reaction mixture was removed and added to a 
quenching plate containing 100 µL of 10% TFA (in water) and stored in ice. Following 
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the collection of all samples, quenching plate was filtered (2,000 rpm, 4 ºC, 10 min). The 
filtrate was removed and assayed by HPLC. 
The apparent first-order degradation rate constants were determined by plotting 
the natural logarithm of test compound remaining as a function of time. The slopes of 
these plots equal to negative rate constant (k). The degradation half-lives were then 
estimated by the equation: 
t1/2 = 0.693/k 
 
Hydrolysis in pH 6.0 uptake buffer and pH 7.4 phosphate buffer. 
The hydrolysis in buffer was carried out the same way as above except each 
reaction tube contains 749.25 µL of uptake buffer (pH 6.0, 140 mM NaCl, 5.4 mM KCl, 
1.8 mM CaC12, 0.8 mM MgSO4, 5 mM D-glucose, and 25 mM MES) or 10 mM 
phosphate buffer (pH 7.4), and quenching plate contains 100 µL of 0.1% TFA (in water). 
 
hVACVase-mediated hydrolysis. 
hVACVase was overexpressed and purified from Escherichia coli as described 
previously[22]. The protein concentration was determined by Bio-Rad DC assay 
(Hercules, CA) with bovine serum albumin as a standard. The kinetic parameters of 
hVACVase-catalyzed hydrolysis were determined as follows. Kinetic measurements 
were carried out in 50 mM HEPES (pH 7.4) buffer at 37°C. After preincubation of the 
buffer for 5 min, hVACVase was added, and then the reaction was initiated by the 
addition of substrate. Aliquots were taken at different time points and quenched by 
adding to same volume of 10% (v/v) trifluoroacetic acid.  Initial velocities were 
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calculated from the linear time course for the product formation. The kinetic parameters 
Km and Vmax were determined by fitting the initial velocity data to the Michaelis-Menten 
equation by the nonlinear least-square regression analysis in GraphPad Prism software 
version 4.01. The kcat value was calculated from Vmax/[enzyme]0 based on the 28.83-kDa 
molecular mass of hVACVase. Specific activity of valacyclovir was routinely monitored 




H]Gly-Sar uptake inhibition. 
The affinity of test compounds to hPEPT1 transporter was evaluated by 
measuring their ability to inhibit the uptake of [
3
H]Gly-Sar, a standard hPEPT1 substrate, 
in HeLa/hPEPT1 cells. Prior to experiment, HeLa cells were grown in 12-well plates for 
5 days and infected with adenovirus containing hPEPT1 3 days before experiment.[23] 
Cells were washed twice with uptake buffer (pH 6.0, 140 mM NaCl, 5.4 mM KCl, 1.8 
mM CaC12, 0.8 mM MgSO4, 5 mM D-glucose, and 25 mM MES) and incubated with 10 
µM Gly-Sar (9.9 µM Gly-Sar and 0.1 µM [
3
H]Gly-Sar) and various concentrations (0.05-
5 mM) of test compounds in 0.3 mL uptake buffer for 30 min in an atmosphere of 5% 
CO2 and 90% relative humidity at 37°C. After 30 min, the donor solutions were aspirated 
and the cells were washed three times with ice-cold uptake buffer and solubilized with 
0.1% SDS. Aliquots of the suspensions were used for scintillation counting (Beckman LS 
6000SC). IC50 values were determined by fitting the data to the one site competition 






The carrier-mediated uptake of the test compounds was screened in 
HeLa/hPEPT1 cells and nomal HeLa cells. Prior to experiment, HeLa cells were grown 
in 12-well plates for 5 days, and infected with adenovirus containing hPEPT1 3 days 
before experiment.[23] Cells were washed with uptake buffer (pH 6.0, 140 mM NaCl, 5.4 
mM KCl, 1.8 mM CaC12, 0.8 mM MgSO4, 5 mM D-glucose, and 25 mM MES) and 
incubated with 1 mL/well of fresh uptake buffer in an atmosphere of 5% CO2 and 90% 
relative humidity at 37°C. After 15 min, uptake buffer was removed and 0.5 mL of 
freshly prepared test compound solution (1 mM) in uptake buffer was added to each well. 
The cell plate was incubated at 37°C for 60 min. Then the cells were washed twice with 
ice-cold Dulbecco's Phosphate Buffered Saline, and collected in 10 mM phosphate buffer 
(pH 7.4) with cell scrapers. The cell suspension was ultrasonicated in ice bath, and cell 
lysate was treated with ice-cold trifluoroacetic acid (final concentration of 7%), vortexed, 
and centrifuged for 10 min at 10,000 rpm. The supernatant was then filtered (0.22 µm) 
and analyzed by HPLC. Control experiments were performed in normal HeLa cells. The 
protein amount of each sample was determined with the Bio-Rad DC Protein Assay using 
bovine serum albumin as a standard. 
 
Caco-2 monolayer permeability studies. 
Caco-2 cells were grown on 6-well collagen-coated transwell inserts (Corning, 3.0 
µm pore size; area 4.67 cm
2
) and permeability studies were performed 22 to 23 days post-
seeding. Transepithelial electrical resistance (TEER) was monitored before and after 
experiment. Each well was rinsed with 1.5 mL of MES buffer (pH 6.0, 140 mM NaCl, 
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5.4 mM KCl, 1.8 mM CaC12, 0.8 mM MgSO4, 5 mM D-glucose, and 25 mM MES) at 
the apical side and 2.5 mL of HEPES buffer (pH 7.5, 140 mM NaCl, 5.4 mM KCl, 1.8 
mM CaC12, 0.8 mM MgSO4, 5 mM D-glucose, and 25 mM HEPES) at the basolateral 
side. Then 1.5 mL of MES buffer and 2.5 mL of HEPES buffer were added to the apical 
side and basolateral side of each well respectively and the plate was incubated in an 
atmosphere of 5% CO2 and 90% relative humidity at 37°C for 15 min. Experiments were 
initiated by replacing the apical buffer with 1.5 mL of 200 µM test compound solution in 
MES buffer and the basolateral buffer with 2.5 mL of fresh HEPES buffer and incubating 
the plate at 37 °C. 200 µL aliquots of the basolateral receiver solution were withdrawn at 
predetermined intervals and replaced with fresh HEPES buffer. The concentrations were 
determined by HPLC. 
The apparent permeability (Papp; cm/s) across Caco-2 cell monolayers was 
calculated using the following equation: 
Papp = (1/C0A) (dQ/dt) 
Where C0 is the initial test compound concentration in the donor solution, A is the 
surface area of the exposed monolayer, and dQ/dt is the steady-state appearance rate of 
the test compound in the receiver solution.  
 
Rat perfusion studies. 
Male albino Wistar rats (Charles River, IN) weighing 250-280 g were used for all 
perfusion studies. Prior to each experiment, the rats were fasted over night (12-18 h) with 




The procedure for the in situ single-pass intestinal perfusion followed previously 
published reports.[24, 25] Briefly, rats were anesthetized with an intra-muscular injection 
of 1 mL/kg of ketamine-xylazine solution (9%:1%, respectively) and placed on a heated 
surface maintained at 37°C (Harvard Apparatus Inc., Holliston, MA). The abdomen was 
opened by a midline incision of 3-4 cm. A jejunal segment of approximately 10 cm was 
carefully exposed and cannulated on two ends with flexible PVC tubing (2.29 mm i.d., 
inlet tube 40 cm, outlet tube 20 cm, Fisher Scientific Inc., Pittsburgh, PA). Care was 
taken to avoid disturbance of the circulatory system, and the exposed segment was kept 
moist with 37°C normal saline solution (Hospira, Lake Forest, IL). The isolated segment 
was rinsed with saline solution in order to clean out any residual debris.  
The perfusion buffer (pH 6.5, 10 mM MES, 135 mM NaCl, 5 mM KCl, 0.1 
mg/mL phenol red, 0.4 mg/mL metoprolol, and 0.1 mM test compound) was incubated in 
a 37°C water bath. At the start of the study, perfusion buffer was pumped through the 
jejunal segment at a flow rate of 0.2 mL/min (Watson Marlow Pumps 323S, Watson-
Marlow Bredel Inc, Wilmington, MA). Phenol red was added to the perfusion buffer as a 
nonabsorbable marker for measuring water flux. Metoprolol was co-perfused as a 
compound with known permeability that serves as a marker for the integrity of the 
experiment and as a reference standard for permeability in close proximity to the 
low/high permeability class boundary.[26] The perfusion buffer was first perfused for 1 h 
in order to ensure steady state conditions (as also assessed by the inlet over outlet 
concentration ratio of phenol red which approaches 1 at steady state). Following reaching 
steady state, samples were taken in 10 min intervals for 1 h (10, 20, 30, 40, 50, and 60 
min). All samples including perfusion samples at different time points, original drug 
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solution, and inlet solution taken at the exit of the syringe were immediately assayed by 
HPLC. Following the termination of the experiment, the length of the perfused intestinal 
segment was accurately measured. 
The effective permeability (Peff) in the in situ rat perfusion experiments was 
calculated using the following equation: 
Peff = [ -Q  ln (Cout/Cin )’] / 2πRL 
 Where Q is the perfusion flow rate (0.2 mL/min), R is radius of the intestine, L is 
the perfused intestinal lenth, Cin and Cout are the inlet and outlet solution concentrations, 
respectively. The latter was corrected by multiplying the outlet concentration with 
[phenol red]in/[phenol red]out in order to account for water flux. 
 
HPLC analysis. 
The concentrations of test compounds were determined on a Waters HPLC 
system (Waters Inc., Milford, MA). The HPLC system consisted of two Waters pumps 
(Model 515), a Waters auto-sampler (WISP model 712) and a Waters UV detector (996 
Photodiode Array Detector). The system was controlled by Waters Millennium 32 
software (Version 3.0.1). Samples were resolved in an Agilent ZORBAX Eclipse XDB-
C18 column (3.5 µm, 4.6 × 150 mm) equipped with a guard column. The mobile phase 
consisted of 0.1% (v/v) TFA in milli-Q water (solvent A) and 0.1% (v/v) TFA in 
acetonitrile (solvent B) with the solvent B gradient changing from 2-30% at a rate of 
2%/min during a 20 min run. The retention times for 3-HPG, Val-3-HPG, Ile-3-HPG, 
Phe-3-HPG, D-Val-3-HPG, acyclovir and valacyclovir were 6.7, 9.7, 11.2, 12.1, 9.7, 4.9 
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and 7.9 minutes, respectively. The detection wavelength was 235 nm for 3-HPG and its 
amino acid esters and 254 nm for acyclovir and valacyclovir. 
 
Statistical analysis.  
All the [
3
H]Gly-Sar uptake inhibition and animal experiments were n=4 unless 
stated otherwise, and all the hydrolysis, direct uptake and Caco-2 permeability 
experiments were performed in triplicate. The data are presented as mean ± SEM. To 
determine statistically significant differences among the experimental groups, the two-
tailed nonparametric Mann-Whitney U test was used for two-group comparison and one-
way analysis of variance followed by Dunnett’s test was performed for comparison of 
several groups against one control group. The difference was termed significant when p-
value is smaller than 0.05. 
 
Results 
Synthesis of 3-HPG and its valine, isoleucine and phenylalanine esters. 
To synthesize 3-HPG, 3-amino benzyl alcohol was treated with 1,3-bis(tert-
butoxycarbonyl)-2-methyl-2-thiopseudourea to convert the amino group to the Boc-
protected guanidino group. Followed by cleavage of the Boc group, 3-HPG was obtained 
as TFA salt (Scheme 2.3). 
Amino acid esters were synthesized by coupling intermediate 2 and Boc-protected 





Hydrolysis in buffer and cell homogenates. 
Hydrolysis studies of 3-HPG and its L-amino acid esters were conducted in buffer 
and cell homogenates and the estimated half-lives (t1/2) obtained from linear regression of 
pseudo-first-order plots are shown in Table 2.1. The half-life of the reference amino acid 
ester prodrug valacyclovir is also listed for comparison. In all buffers and cell 
homogenates, the parent compound 3-HPG exhibited good stability, which makes it an 
excellent model compound for subsequent studies. All the L-amino acid esters were also 
stable in pH 6 uptake buffer, and relatively stable in pH 7.4 phosphate buffer. In both 
HeLa and Caco-2 cell homogenates, the estimated half-lives of L-amino acid esters were 




The estimated Michaelis-Menten kinetic parameters of 3-HPG esters as well as 
valacyclovir are listed in Table 2.2. All L-amino acid esters of 3-HPG showed low Km 
values ranging from 9 to 207 µM. Interestingly, the kcat values followed the same order as 
Km values (Phe-3-HPG > Val-3-HPG > Ile-3-HPG), so the specificity constant, kcat/Km, 
did not differ as much as Km or kcat value itself. When compared with valacyclovir, Val-3-
HPG exhibited lower, but not significantly different Km value. All the 3-HPG esters 
showed higher specificity constant than valacyclovir, clearly indicating that they are good 







H]Gly-Sar uptake inhibition. 
The IC50 values of 3-HPG, its valine, isoleucine and phenylalanine esters to 
inhibit [
3
H]Gly-Sar uptake in HeLa/hPEPT1 cells are listed in Table 2.3. The amino acid 
benzyl esters were used for comparison to obtain the contribution of the guanidino group. 
Valacyclovir, a known substrate of hPEPT1, was used as positive control. 
The parent compound 3-HPG showed high IC50 value in [
3
H]Gly-Sar uptake 
inhibition study. Valine and isoleucine esters of 3-HPG, however, exhibited lower IC50 
values than valacyclovir, indicating good affinity to the hPEPT1 transporter. Phe-3-HPG 
also showed some affinity to hPEPT1, although it was not as good as valacyclovir. 
Comparing with the corresponding benzyl esters, all the 3-HPG esters showed similar or 
higher affinity to hPEPT1.  
 
Direct uptake. 
The results of direct uptake study in HeLa/hPEPT1 cells and normal HeLa cells 
are summarized in Table 2.4. The parent compound 3-HPG, its valine and isoleucine 
esters and valacyclovir were very stable in donor solution (> 95% remaining after 1 h). 
Phe-3-HPG was also relatively stable (> 80% remaining after 1h). Valacyclovir, a known 
substrate of hPEPT1 transporter, showed more than 25-fold higher uptake in 
HeLa/hPEPT1 cells compared to that in normal HeLa cells. The 3-HPG esters displayed 
8- to more than 25-fold increased uptake in HeLa/hPEPT1 cells compared with in normal 
HeLa cells, whereas 3-HPG only showed little enhancement. In HeLa/hPEPT1 cells, the 




Caco-2 monolayer permeability studies. 
The permeability of 3-HPG and its amino acid esters across Caco-2 monolayers is 
shown in Figure 2.1. Val-3-HPG and Ile-3-HPG exhibited higher permeability than the 
parent compound 3-HPG and the permeability of Val-3-HPG was comparable to 
valacyclovir. Because both Val-3-HPG and Ile-3-HPG were stable in the donor solution 
(Table 2.5), and only the parent compound was detected in the receiver solution, most of 
the esters appeared to be metabolized in the cells prior to penetration of the basolateral 
membrane. Phe-3-HPG did not show significantly different permeability than 3-HPG. 
However, due to its low stability in the donor solution (Table 2.5), the permeability may 
be underestimated. The stability issues, the lower affinity to hPEPT1 transporter and 
uptake in HeLa/hPEPT1 cells indicated that Phe-3-HPG was not a favorable candidate for 
in vivo studies.      
In contrast to Val-3-HPG, no transport of D-Val-3-HPG was detected. Since D-
Val-3-HPG and Val-3-HPG are enantiomers, they should have similar permeability if the 
transport mechanism is predominantly passive diffusion. The much higher permeability 
of Val-3-HPG suggested that the transport was carrier-mediated. To identify the 
transporter(s) involved in Val-3-HPG transport, we also investigated the effect of 
inhibitors on Val-3-HPG permeability, including hPEPT1 inhibitors Gly-Sar and 
cephalexin, amino acid transporter inhibitors L-valine and L-arginine, and organic cation 
transporter (OCT) inhibitor tetraethylammonium (TEA). Only hPEPT1 inhibitors reduced 
Val-3-HPG permeability, suggesting hPEPT1 playing a dominant role in Val-3-HPG 




Rat perfusion studies. 
The effective permeability (Peff) of 3-HPG, Val-3-HPG and Ile-3-HPG in rat 
jejunum perfusion study is shown in Figure 2.3. Metoprolol was co-perfused with the test 
compounds as a reference standard for permeability in close proximity to the low/high 
permeability class boundary. It can be seen that Val-3-HPG and Ile-3-HPG exhibited 
higher or similar permeability compared to metoprolol, respectively, whereas the 
permeability of 3-HPG was very low. Hence, the amino acid ester prodrug approach 




The positively charged guanidino functionality provides favorable interactions 
with important drug targets such as thrombin and influenza neuraminidase. However, the 
permanent positive charge at all relevant pHs can also cause low membrane permeability 
and poor oral bioavailability. To overcome this drug delivery barrier, we have utilized a 
targeted prodrug strategy, aiming to exploit hPEPT1 as the prodrug transport carrier and 
hVACVase as the predominant activating enzyme. This prodrug approach may have the 
advantages of higher transport accompanied by more predictable activation, leading to 
favorable properties for oral delivery. 
In order to increase oral bioavailability of low permeability drugs, different 
classes of amino acids, including acidic, basic, hydrophobic and aromatic, were used as 
promoieties targeting drugs to oligopeptide transporters such as hPEPT1 and intracellular 
activating enzymes such as hVACVase.[9-17] Among all the amino acid ester prodrugs, 
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valine, isoleucine and phenylalanine derivatives were frequently studied. Valine and 
isoleucine ester prodrugs showed consistently high affinity to hPEPT1 transporter and 
enhanced drug permeability in both cell culture and animal models. In addition, the 
success of valacyclovir and valganciclovir suggested that valine may be one of the safest 
choices as promoiety for a new compound. Phenylalanine esters of floxuridine and 
gemcitabine also showed good affinity to hPEPT1 transporter and significantly increased 
the uptake in hPEPT1 overexpressed HeLa cells or transport in Caco-2 cells compared 
with the parent drugs. However, the phenylalanine esters of levovirin and cytarabine 
didn’t exhibit substantial improvement for Caco-2 permeability and absorption in rats. 
Most of the valine, isoleucine and phenylalanine ester prodrugs showed good chemical 
stability and rapid enzymatic activation, and both valine and phenylalanine promoieties 
were proven to be preferred by hVACVase. Isoleucine esters were not studied for 
hVACVase-catalysed activation; however, the effective activation of isoleucine ester 
prodrugs suggested that it may also be a good hVACVase substrate. In order to rule out 
the negative effects of amino acid side chains, only the well-studied and most promising 
amino acid promoieties, valine, isoleucine and phenylalanine, were used in this study.  
A primary concern of this research was whether the guanidino functionality can 
be tolerated and transported by hPEPT1 transporter. In [
3
H]Gly-Sar uptake inhibition 
studies, both the valine and isoleucine esters of 3-HPG showed high affinity to hPEPT1, 
while the comparison between benzyl esters and 3-HPG esters did not show significant 
difference. Therefore, at least in the framework of this research, there was no evidence 
that the guanidino functionality hindered the binding to hPEPT1 transporter. The results 
in direct uptake, Caco-2 monolayer permeability and rat perfusion studies further support 
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our hypothesis that the amino acid esters of 3-HPG can be transported by hPEPT1 for 
improved permeability. In normal HeLa cells, the uptake of the amino acid esters was 
even lower than the parent compound 3-HPG. However, in HeLa/hPEPT1 cells, the 
amino acid esters showed 2.6- to 9-fold higher uptake than 3-HPG, which can be 
attributed to hPEPT1-mediated transport. In the same fashion, both valine and isoleucine 
esters of 3-HPG exhibited considerably higher permeability across Caco-2 monolayers 
than the parent compound. The low permeability of D-Val-3-HPG and the studies with 
inhibitors clearly demonstrate that this enhancement can be attributed to hPEPT1. In rat 
perfusion studies, the effective permeability of Val-3-HPG and Ile-3-HPG exceeded or 
matched the high-permeability drug metoprolol, indicating high intestinal permeability. 
Taken together, these results demonstrate that it is feasible to target guanidino-containing 
compounds to hPEPT1 transporter for enhanced oral absorption. Up to now, the amino 
acid ester prodrug strategy has mainly been limited to nucleoside analogues. The positive 
results with the guanidino functionality illustrated great promise to expand this strategy to 
other polar and charged low-permeability drugs.  
In addition to the guanidino functionality, this study provided more insights into 
the influence of amino acid promoieties on the hPEPT1-mediated transport. Among the 
three amino acid esters, valine ester exhibited the highest permeability in both cell culture 
and rat perfusion model, which is consistent with 5’-amino acid ester prodrugs of 
floxuridine,[10] gemcitabine,[14] levovirin,[15] and cytarabine.[16] The phenylalanine 
ester exhibited the lowest affinity to hPEPT1, smallest uptake enhancement and no 
significant improvement in permeability studies. However, the poor stability in the donor 
solution of Caco-2 monolayer (Table 2.5) inevitably leads to underestimation of the 
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permeablility. This is also the case with 5’-phenylalanine ester of levovirin,[15] where 
the low Caco-2 permeability accompanied low apical stability. Indeed, the 5’-
phenylalanine ester prodrugs of floxuridine and gemcitabine exhibited enhanced uptake 
and permeability compared to corresponding parent drugs. Therefore, phenylalanine 
should not be excluded as a promising promoiety for hPEPT1 targeting. However, when 
phenylalanine ester prodrugs are designed, attention must be paid to make sure the 
prodrug is relatively stable in the brush border membrane to realize their full potential.  
When utilizing the prodrug approach to increase oral absorption, the activation 
mechanism is often overlooked. As long as the parent drug can be regenerated, the 
activation will be considered successful, and the enzymes responsible for the prodrug 
activation may not capture much further attention. However, the activation process is 
actually the unique and one of the most critical steps for a prodrug to exert therapeutic 
effect. If the possible activating enzymes are identified, prodrugs can be designed to 
target these enzymes, which greatly increase the chances for the effective production of 
the parent drug. Although the amino acid ester prodrug strategy has been applied to many 
nucleoside analogues and improved the oral absorption by targeting hPEPT1, the 
activation was not well-studied and was considered nonspecific until the identification of 
the amino acid ester prodrug-activating enzyme hVACVase.[7] hVACVase is at least one 
of the primary enzymes activating valacyclovir in vivo and is capable of activating many 
other amino acid ester prodrugs of nucleoside analogues.[17] The large leaving group-
accommodating groove of hVACVase makes it an ideal target for prodrug design. The 
data presented in this research demonstrate that a positively charged leaving group, 3-
HPG, can be well tolerated by hVACVase, although whether the guanidino functionality 
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helped the binding is still unclear. The high specificity constant (kcat/Km) of all the L-
amino acid esters of 3-HPG is consistent with their fast activation in Caco-2 cell 
homogenates as well as Caco-2 monolayer permeability studies. Therefore, hVACVase 
can be exploited as the target for activating amino acid ester prodrugs of guanidino-
containing drugs. At the same time, the possibility that other enzymes can also contribute 
to the activation of amino acid ester prodrugs cannot be ruled out. We have estimated the 
hydrolysis rate of 3-HPG esters in Caco-2 cell homogenates with the kinetic data in 
hVACVase, based on the assumption that hVACVase was the predominant enzyme 
activating valacyclovir. After comparison with the hydrolysis data in Caco-2 
homogenates, it turns out that hVACVase was also the primary enzyme responsible for 
Val-3-HPG and Ile-3-HPG hydrolysis, whereas the hydrolysis of Phe-3-HPG may 
involve other enzymes.   
Because of the success with the model compound 3-HPG, Sheeba Varghese 
Gupta and Deepak Gupta et al applied this prodrug approach to the poorly absorbed anti-
influenza agents zanamivir and guanidine oseltamivir carboxylate (GOCarb). By using an 
acyloxyester linker, valine and isoleucine were covalently connected to zanamivir and 
GOCarb (Scheme 2.4). In Caco-2 cells, all the prodrugs showed affinity to hPEPT1 
transporter by inhibiting the uptake of hPEPT1 substrate [
3
H]Gly-Sar, and the IC50 values 
of GOC-Val and GOC-Ile were lower than valacyclovir. On the other hand, the parent 
drugs zanamivir and GOCarb didn’t show much inhibition. In HeLa/hPEPT1 cells, Zan-
Val, GOC-Val and GOC-Ile exhibited elevated uptake (2-6 fold) than in normal HeLa 
cells. In Caco-2 cell transport study, the permeability of all the prodrugs were higher than 
corresponding parent drugs (2-12 fold). Most importantly, Zan-Val and GOC-Val showed 
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at least similar rat jejunal permeability to metoprolol, suggesting high oral absorption. All 
the prodrugs were rapidly metabolized in Caco-2 cell homogenates presumably by 
hVACVase and other activating enzymes. These results further confirmed the feasibility 
of this transporter- and enzyme-targeted prodrug approach for improved oral absorption 
of guanidino-containing drugs. (All the data in this paragraph came from unpublished 
manuscripts prepared by Sheeba Varghese Gupta and Deepak Gupta et al.)      
In summary, the amino acid esters of a guanidino-containing model compound 
exhibited high affinity to hPEPT1 transporter, leading to enhanced intestinal permeability 
accompanied by hVACVase-mediated activation to the parent compound. Combined with 
the study of zanamivir and GOCarb prodrugs, the results suggested that it is feasible to 
apply the same strategy to other poorly absorbed guanidino analogues. This transporter- 
and enzyme-targeted approach makes the prodrug design more rational and less 
empirical, with the ability to mechanistically control the two most important aspects 


























R = amino acid side chain  
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Table 2.1. Estimated half-lives in pH 6 uptake buffer, pH 7.4 phosphate buffer, HeLa cell 
homogenates and Caco-2 cell homogenates (mean ± SEM; n=3). 
 
 Half-lives (min) 
 





3-HPG stable* stable* stable* stable*  
Val-3-HPG  stable* 493.6 ± 10.4 20.3 ± 0.7 4.8 ± 0.2  
Ile-3-HPG  stable* 704.8 ± 9.7 137.2 ± 3.6 59.6 ± 2.3  
Phe-3-HPG  stable** 261.8 ± 5.0 << 5 << 1  
valacyclovir stable* 829.4 ± 25.0 142.2 ± 1.2 31.3 ± 0.8  










Table 2.2. Michaelis-Menten kinetic parameters of 3-HPG esters and valacyclovir for 
hVACVase-mediated hydrolysis (mean ± SEM; n=3). 
 







Val-3-HPG 46 ± 5 321 ± 9 154 ± 4 3370 ± 460 
Ile-3-HPG 9.0 ± 1.2 30 ± 1 14 ± 1 1580 ± 260 
Phe-3-HPG 207 ± 16 718 ± 16 345 ± 8 1660 ± 160 







H]Gly-Sar uptake inhibition in HeLa/hPEPT1 cells (mean ± SEM; 
valacyclovir, n=6; others n=4).   
 
 IC50 (mM) 
3-HPG >3 
Val-3-HPG 0.65 ± 0.04 
Val-OBz 0.39 ± 0.04 
Ile-3-HPG  0.63 ± 0.04 
Ile-OBz 1.05 ± 0.13 
Phe-3-HPG  2.33 ± 0.45 
Phe-OBz > 3 















Table 2.4. Direct uptake and stability in HeLa/hPEPT1 and normal HeLa cells (mean ± 
SEM; n = 3). 
 
 HeLa/hPEPT1 cells HeLa cells  
 uptake 
(nmol/mg 









3-HPG 5.5 ± 0.6 - 3.8 ± 0.1 - 1.4 ± 0.2 
Val-3-HPG  50.2 ± 1.6 96.9 ± 0.0 < 2 98.0 ± 0.1 > 25 
Ile-3-HPG 27.7 ± 1.4 98.7 ± 0.0 < 2 99.0 ± 0.1 >13 
Phe-3-HPG  14.8 ± 1.7 83.8 ± 0.3 1.7 ± 0.2 87.2 ± 0.9 8.8 ± 2.0 
valacyclovir 5.5 ± 0.3 96.8 ± 0.1 < 0.2 99.2 ± 0.0 > 25 










Table 2.5. Stability in apical side during permeability study across Caco-2 monolayers 
(mean ± SEM; n = 3). 
 
 Stability* (%) 
3-HPG - 
Val-3-HPG  86.5 ± 0.3 
Ile-3-HPG  96.6 ± 0.6 
Phe-3-HPG 3.9 ± 2.0 
D-Val-3-HPG  98.8 ± 0.1 
valacyclovir 94.7 ± 0.3 





Figure 2.1. Apparent apical-to-basolateral permeability coefficient (Papp) across Caco-2 






Figure 2.2. Apparent apical-to-basolateral permeability coefficient (Papp) of Val-3-HPG 
without or with 5 mM inhibitors across Caco-2 monolayers (mean ± SEM; n=3; * 





Figure 2.3. Rat jejunal membrane permeability (mean ± SEM; metoprolol, n=12; others, 
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Majority of the work in this chapter has been published entitled “Enhancing the 
intestinal absorption of molecules containing the polar guanidino functionality: a double-














The effect of leaving groups on hVACVase-catalyzed prodrug activation 
 
Introduction 
Amino acid ester or amide prodrug strategy is a successful approach to improve 
oral absorption of low-permeability drugs by targeting oligopeptide transporters.[1-6] 
Following absorption, the prodrug needs to be metabolized chemically or enzymatically 
to the active parent drug. We have identified an amino acid ester prodrug-activating 
enzyme, hVACVase,[7] which is believed to be one of the major enzymes for the 
activation of valine ester prodrugs valacyclovir and valganciclovir. hVACVase also 
effectively hydrolyzes many other amino acid esters of nucleoside analogues and simple 
alcohols.[8, 9] Its potential to serve as a universal prodrug-activating enzyme for amino 
acid ester and amide prodrugs made hVACVase an interesting research subject. 
hVACVase is a serine hydrolase with a catalytic triad S122-H255-D227. The very 
specific preference for amino acid analogues is due to the electrostatic interaction 
between the critical residue D123 and the free amino group of the substrate. Based on our 
previous kinetic studies, the amino acid side chain of the substrate has a significant effect 
on both the Km and Vmax values. As an example, the Km values (in mM) and Vmax values 
(in nmol/min/µg) of a series of floxuridine (FUdR) prodrugs are proline-FUdR 1.45, 556, 




9 different amino acid benzyl esters, the specific activities of hVACVase-catalyzed 
activation range from 0 to 5148 units/mg.[9] The effect of amino acid promoieties on the 
hVACVase-catalyzed hydrolysis is able to aid the prediction of the prodrug activation 
and the rational design of new prodrugs. 
Apart from the free amino group and amino acid side chain, the effect of leaving 
groups is also essential. Currently many amino acid ester prodrugs were proved to be 
hVACVase substrates and the leaving groups include nucleoside analogues acyclovir, 
ganciclovir, floxuridine, gemcitabine, zidovudine and BDCRB, as well as simple alcohols 
such as methanol, ethanol and benzyl alcohol.[8, 9] This is consistent with the large 
leaving group-accommodating groove revealed by the crystal structure. However, 
although the phenylalanine benzyl and ethyl esters are hVACVase substrates (specific 
activities are 358.3 and 75.3 units/mg, respectively), phenylalanine t-butyl ester is not a 
substrate.[9] Also, the valine 5’-floxuridine has a higher Vmax value compared with valine 
3’-floxuridine ester (Vmax values in nmol/min/µg are 148 and 33, respectively).[8] Those 
results suggested that the alcohol leaving groups may have an effect on hVACVase 
specificity. Also, hVACVase did not exhibit significant hydrolytic activity towards a 
series of amides, including Lys-p-NA, Leu-p-NA, Pro-p-NA, Phe-p-NA, Val-p-NA and 
Gly-Pro-p-NA.[8] This may be due to the much more stable amide bond compared with 
the ester bond, suggesting hVACVase may not be a good activating enzyme for amide 
prodrugs. The ten-fold different Km values of prodrugs valacyclovir and valganciclovir 
(0.19 and 1.90 mM, respectively) indicated that the leaving group may also affect binding 




future prodrug design, a more careful investigation of the leaving group effect will be 
crucial. 
As a serine hydrolase, the hydrolysis catalyzed by hVACVase is presumably a 
three-step reaction as shown in the following scheme:[10] 
 
 












It can be seen that the effect of the leaving groups relies on the rate-limiting step, 
which is either acylation or deacylation. Because the leaving group (alcohol or amine) is 
released from the enzyme in the acylation step, it will only have an effect on the k2 value. 
If the acylation step is rate-limiting (k2 << k3), the kcat value will be affected by the 
leaving group, and Km value will approach Ks. If the deacylation step is rate-limiting 
(k2 >> k3), the kcat value will be independent of the leaving group, and Km value will be a 




The specific aim of this chapter was to investigate the effect of leaving groups on 
the hVACVase-catalysed prodrug activation. We have determined the kinetic parameters 
of a series of valine esters (Val-3-HPG, valacyclovir, valine benzyl ester, valine p-
nitrobenzyl ester), phenylalanine esters (Phe-3-HPG, phenylalanine benzyl ester, 
phenylalanine ethyl ester, phenylalanine methyl ester) and valine amide of [3-
(aminomethyl)phenyl]guanidine, Val-3-APG (Scheme 3.1 and 3.2). This approach 
allowed us to determine the rate-limiting step of hVACVase-catalyzed hydrolysis and the 
effect of leaving groups on the binding affinity and specific activity, and further lead to 




Boc-L-valine and N,N,N′,N′-tetramethyl-O-(1H-benzotriazol-1-yl)uronium 
hexafluorophosphate (HBTU) were obtained from Calbiochem-Novabiochem (San 
Diego, CA). Valacyclovir was a gift from GlaxoSmithKline, Inc. (Research Triangle 
Park, NC). L-Valine 4-nitrobenzyl ester hydrobromide was obtained from Chem-Impex 
International, Inc. (Wood Dale, IL). High-performance liquid chromatography (HPLC) 
grade acetonitrile was obtained from Fisher Scientific (St. Louis, MO). 3-
Aminobenzonitrile, 1,3-bis(tert-butoxycarbonyl)-2-methyl-2-thiopseudourea, mercury(II) 
chloride, Pd/C, 2M NH3/EtOH, trifluoroacetic acid (TFA), N,N-diisopropylethylamine, L-
valine benzyl ester hydrochloride, L-phenylalanine benzyl ester hydrochloride, L-
phenylalanine methyl ester hydrochloride, L-phenylalanine ethyl ester hydrochloride, and 




Cell culture reagents were obtained from Invitrogen (Carlsbad, CA), and cell culture 
supplies were obtained from Corning (Corning, NY) and Falcon (Lincoln Park, NJ). All 





To a stirred suspension of 3-aminobenzonitrile (118 mg, 1.0 mmol), 1,3-bis(tert-
butoxycarbonyl)-2-methyl-2-thiopseudourea (290 mg, 1 mmol) and mercury(II) chloride  
 (353 mg, 1.3 mmol) in 5 mL of dry tetrahydrofuran (THF), 405 mg (4.0 mmol) of 
triethylamine was added dropwise under argon. After 2 hours, the reaction was stopped 
and reaction mixture was diluted with ethyl acetate and filtered through Celite
®
. Solvents 
were removed and the residue was dissolved in 40 mL of ethyl acetate and washed with 
10% w/v citric acid, saturated NaHCO3 and brine. The organic phase was dried over 
anhydrous MgSO4 and concentrated in vacuo. Product 7 was purified by column 
chromatography (hexanes : ethyl acetate, 20 : 1) to give 327.9 mg white powder. Yield: 
91.0%. 
1
H NMR (CDCl3) δ 11.65 (1H, br), 10.55 (1H, br), 8.11 (1H, s), 7.77 (1H, d, J = 




A mixture of 7 (150 mg, 0.416 mmol) and Pd/C (10 wt % palladium on activated carbon, 
150 mg) in 100 mL of 2M NH3/EtOH was hydrogenated in a Parr apparatus at 45 psi and 
room temperature for 9 h. The reaction mixture was filtered through Celite
®
. The solvents 
were removed and product was purified by column chromatography (dichloromethane : 
methanol, 15 : 1) to give 80.0 mg light yellow gum. Yield: 52.7%. 
1




11.65 (1H, br), 10.37 (1H, br), 7.56 (1H, s), 7.52 (1H, d, J = 7.8 Hz), 7.32 (1H, dd, J = 7.8 




[3-(Aminomethyl)phenyl]guanidine (3-APG, 9). 
24.8 mg of 8 was dissolved in 2.2 mL of trifluoroacetic acid (TFA):CH2Cl2 (1:1.2) and 
stirred at room temperature for 2 hours. Then solvents were removed and the residue was 
dissolved in 0.1 % TFA, filtered and lyophilized. The raw product was further purified by 
semi-prep HPLC to give 15.4 mg white solid. Yield: 57.7%. 
1
H NMR (CD3OD) δ 7.57 
(1H, dd, J = 7.9 Hz, 7.9 Hz), 7.44 (2H, m), 7.36 (1H, d, J = 7.9 Hz), 4.18 (2H, s); ESI-





To a stirred solution of 8 (12.6 mg, 0.035 mmol), Boc-L-valine (9.1 mg, 0.042 mmol) and 
N,N,N′,N′-tetramethyl-O-(1H-benzotriazol-1-yl)uronium hexafluorophosphate (HBTU, 
16.0 mg, 0.042 mmol) in 1 mL of anhydrous CH2Cl2, 18 µl of N,N-diisopropylethylamine 
were added dropwise under argon. The reaction mixture was stirred at ambient 
temperature for 3 h and then the solvents were removed. The residue was dissolved in 30 
mL of CH2Cl2 and washed with 10% w/v citric acid, saturated NaHCO3 and brine. The 
organic phase was dried over anhydrous MgSO4 and concentrated in vacuo. The mixture 
was then chromatographed on silica gel (hexanes : ethyl acetate, 5 : 1) to obtain 10 as 
colorless oil. 
1
H NMR (CDCl3) δ 11.65 (1H, br), 10.35 (1H, br), 7.52 (1H, d, J=7.8 Hz), 




(1H, m), 4.43 (2H, d, J=5.6 Hz), 3.92 (1H, m), 2.19 (1H, m), 1.42-1.53 (27 H, m), 0.96 
(3H, d, J=6.8 Hz), 0.91 (3H, d, J=6.8 Hz); ESI-MS: 564.2 (M+H)
+
. 
10 was treated with 2.2 mL of TFA : CH2Cl2 (1:1.2) for 2 hours. Solvents were removed 
and residue was dissolved in 0.1 % TFA, filtered and lyophilized to give 12.86 mg of 11 
as light brown syrup.  Yield of two steps: 74.8%. 
1
H NMR (CD3OD) δ 7.48 (1H, dd, 
J=7.9 Hz, 7.8 Hz), 7.35 (1H, d, J=7.9 Hz), 7.28 (1H, s), 7.23 (1H, d, J=7.8 Hz), 4.49 (2H, 




Hydrolysis of valine and phenylalanine esters in pH 7.4 HEPES buffer. 
Hydrolysis in pH 7.4 HEPES buffer was determined at 37 ºC. The hydrolysis 
reaction was initiated by adding 0.75 µL of test compound solution (200 mM in DMSO) 
to a reaction tube containing 749.25 µL pH 7.4 HEPES buffer. At various time points, 
100 µL of the reaction mixture was removed and added to a quenching plate containing 
100 µL of 1% TFA (in water) and stored in ice. Following the collection of all samples, 
quenching plate was filtered (2,000 rpm, 4 ºC, 10 min). The filtrate was removed and 
assayed by HPLC. 
The apparent first-order degradation rate constants were determined by plotting 
the natural logarithm of test compound remaining as a function of time. The slopes of 
these plots equal to negative rate constant (k). The degradation half-lives were then 
estimated by the equation: 






Hydrolysis of Val-3-APG in pH 7.4 HEPES buffer. 
The hydrolysis reaction was initiated by adding 20 µL of Val-3-APG solution 
(200 mM in DMSO) to a reaction tube containing 380 µL pH 7.4 HEPES buffer and 
incubated at 37 ºC. At various time points (up to 800 h), 85 µL of the reaction mixture 
was removed and added to a quenching tube containing 85 µL of 10% TFA (in water), 
filtered (2,000 rpm, 4 ºC, 10 min), and the filtrate was assayed by HPLC immediately. 
The apparent first-order degradation rate constants were determined by plotting 
the natural logarithm of Val-3-APG percentage (1-[3-APG]/([3-HPG]+[Val-3-APG])) as 
a function of time. The slope equals to negative rate constant (k). The degradation half-
lives were then estimated by the equation: 
t1/2 = 0.693/k 
 
Cell culture. 
Caco-2 cells (passage 23) from American Type Culture Collection (Rockvile, 
MD) were routinely maintained in Dulbecco’s modified Eagle’s medium (DMEM) 
containing 10% fetal bovine serum (FBS), 1% nonessential amino acids, 1 mmol/L 
sodium pyruvate and 1% L-glutamine. Cells were grown in an atmosphere of 5% CO2 
and 90% relative humidity at 37°C. 
 
Val-3-APG hydrolysis in Caco-2 cell homogenates. 
Caco-2 cells were washed with 0.15 M NaCl solution and then collected with 10 
mM phosphate buffer (pH 7.4). The cell suspension was ultrasonicated in ice bath to 




Supernatant was placed in a new tube. The concentration of enzyme was determined as 
protein amount with the Bio-Rad DC assay (Hercules, CA) and adjusted to 500 µg/mL. 
Hydrolysis in cell homogenates was determined at 37 ºC. The hydrolysis reaction 
was initiated by adding 0.75 µL of Val-3-APG (200 mM in DMSO) to a reaction tube 
containing 749.25 µL cell homogenates. At various time points (0, 5, 10, 30, 60 and 120 
min), 100 µL of the reaction mixture was removed and added to a quenching plate 
containing 100 µL of 10% TFA (in water) and stored in ice. Following the collection of 
all samples, quenching plate was filtered (2,000 rpm, 4 ºC, 10 min). The filtrate was 
removed and assayed by HPLC. 
 
hVACVase-mediated hydrolysis. 
hVACVase was overexpressed and purified from Escherichia coli as described 
previously[9] and used for all the test compounds except Val-3-APG. 6×His-tagged 
hVACVase (M - S tag – PDLGTLVPRGSMGM – hVACVase – AAALE - His tag), 
provided by Dr. Zachary Walls, was produced in bacteria, purified by affinity 
chromatography and used for Val-3-APG. The results from the two proteins are 
considered to be comparable due to their very similar specific activity towards 
valacyclovir activation. The protein concentration was determined by Bio-Rad DC assay 
(Hercules, CA) with bovine serum albumin as a standard. The kinetic parameters of 
hVACVase-catalyzed hydrolysis were determined as follows. Kinetic measurements 
were carried out in 50 mM HEPES (pH 7.4) buffer at 37°C. After preincubation of the 
buffer for 5 min, hVACVase was added, and then the reaction was initiated by the 




adding to same volume of 10% (v/v) trifluoroacetic acid.  Initial velocities were 
calculated from the linear time course for the product formation. The kinetic parameters 
Km and Vmax were determined by fitting the initial velocity data to the Michaelis-Menten 
equation by the nonlinear least-square regression analysis in GraphPad Prism software 
version 4.01. The kcat value was calculated from Vmax/[enzyme]0 based on the 28.83-kDa 
molecular mass of hVACVase and 33.38-kDa molecular mass of 6×His-tagged 
hVACVase. Specific activity of valacyclovir was routinely monitored to normalize active 
protein concentration.    
 
HPLC analysis 
The concentrations of test compounds were determined on a Waters HPLC 
system (Waters Inc., Milford, MA). The HPLC system consisted of two Waters pumps 
(Model 515), a Waters auto-sampler (WISP model 712) and a Waters UV detector (996 
Photodiode Array Detector). The system was controlled by Waters Millennium 32 
software (Version 3.0.1). Samples were resolved in an Agilent ZORBAX Eclipse XDB-
C18 column (3.5 µm, 4.6 × 150 mm) or an Agilent ZORBAX SB-Aq column (3.5µm, 4.6 
× 150 mm) equipped with a guard column. The mobile phase consisted of 0.1% (v/v) 
TFA in milli-Q water (solvent A) and 0.1% (v/v) TFA in acetonitrile or 0.1% (v/v) TFA 
in methanol (solvent B). The detection wavelength was 235 nm for 3-HPG, 3-APG, Val-
3-HPG, Phe-3-HPG and Val-3-APG, 254 nm for acyclovir and valacyclovir, 275 nm for 







All the experiments were performed in triplicate unless stated otherwise. The data 
are presented as mean ± SEM. 
 
Results 
Synthesis of 3-APG and its valine amide. 
The synthesis of 3-APG and its valine amide was summarized in Scheme 3.3. 3-
Aminobenzonitrile was treated with 1,3-bis(tert-butoxycarbonyl)-2-methyl-2-
thiopseudourea to convert the free amino group to the Boc-protected guanidino group. 
Then the cyano group was reduced by hydrogenation to afford intermediate 8. 
Deprotection of 8 gives 3-APG. Valine-3-APG was synthesized by coupling intermediate 
8 and Boc-valine followed by deprotection.  
 
Hydrolysis in buffer and cell homogenates. 
The half-lives in pH 7.4 HEPES buffer of valine and phenylalanine analogues 
were shown in Table 3.1 and 3.2. Valacyclovir and valine benzyl ester exhibited about 
two-fold longer half-lives than valine p-nitrobenzyl ester and Val-3-HPG. Compared with 
Val-3-HPG, the hydrolysis of Val-3-APG was five orders of magnitude slower. For the 
phenylalanine esters, the half-lives increased in the following order: Phe-3-HPG < Phe-
OBz < Phe-OMe < PheOEt. 
In contrast to the fast hydrolysis of Val-3-HPG (Table 2.1), the valine amide Val-
3-APG was fairly stable in Caco-2 cell homogenates. During the 2 h incubation time no 





The Michaelis-Menten kinetic parameters of valine derivatives for hVACVase-
mediated hydrolysis were listed in Table 3.3. All the valine esters showed relatively low 
Km values ranging from 14 to 68 µM. The kcat values of valine p-nitrobenzyl ester and 
Val-3-HPG were about 2-fold higher than valacyclovir and valine benzyl ester, following 
the same trend as buffer hydrolysis rate. The valine amide Val-3-APG exhibited much 
higher Km and lower kcat values compared with the esters, suggesting that it is a very poor 
substrate of hVACVase. 
Phe-3-HPG and phenylalanine benzyl ester exhibited high specificity constants as 
shown in Table 3.4, suggesting that they are good hVACVase substrates. However, the 
specificity constants of phenylalanine methyl and ethyl esters were much lower, which 
was mainly due to the higher Km value.  
 
Discussion  
To investigate the effects of leaving groups, the rate-limiting step of hVACVase-
catalyzed reactions must be determined. According to the mechanism of serine 
hydrolases, for a series of esters or amides with same acyl group but different leaving 
groups with diverse lability, k2 values should be different but k3 values should be the 
same because the deacylation step is identical for all the substrates. Therefore, the rate-
limiting step could be determined by comparing kcat (or Vmax) values for the ester and 
amide substrates. A classic example of this strategy was the case of chymotrypsin.[11] As 
shown in Table 3.5, the amide showed about three orders of magnitude lower kcat value 




amide. However, for the esters, although p-nitrophenol is a much better leaving group 
than methanol and ethanol, the very similar kcat value suggested that the deacylation step 
was rate-limiting. In the present study we are using a similar strategy for hVACVase by 
comparing the kcat values of a series of valine and phenylalanine analogs. 
The buffer hydrolysis rate reflects the lability of the leaving groups and therefore 
the k2 value of the hVACVase-catalyzed hydrolysis. The buffer hydrolysis rates of valine 
p-nitrobenzyl ester and Val-3-HPG were two-fold faster than valine benzyl ester, 
consistent with the electron withdrawing effect of the nitro and guanidino groups. The 
order of phenylalanine esters hydrolysis rate was also in correspondence to the leaving 
group lability. The very low acidity of 3-APG makes it a poor leaving group, explaining 
the five orders of magnitude slower buffer hydrolysis of Val-3-APG compared with Val-
3-HPG.  
According to the four to five orders of magnitude difference between the kcat 
values of Val-3-HPG and Val-3-APG, it becomes very clear that for the amide Val-3-
APG, the acylation step (k2) was rate-limiting, which was the same case as chymotrypsin. 
For the valine esters, the kcat values were also different and matched the trend of buffer 
hydrolysis rate, therefore the relationship between the first order rate constant k of buffer 
hydrolysis and kcat was linear (Figure 3.1). It suggested that the lability of leaving groups 
did affect the kcat and opposite to that of chymotrypsin, the acylation step (k2) should be 
rate-limiting. This is more similar to the case of rat liver carboxylesterase-catalyzed 
hydrolysis of acetate esters, where the chain length of the alkyl alcohol leaving group 
significantly affects the reaction rate.[12] However, we cannot rule out the possibility that 




relatively small (up to 2.5-fold). Therefore, more compounds with a broader range of 
labilities need to be tested to prove our hypothesis.  
For the phenylalanine benzyl, methyl and ethyl esters, the kcat value also matched 
the buffer hydrolysis rate, suggesting that the acylation step is rate-limiting. The poor 
linearity between the first order rate constant k of buffer hydrolysis and kcat shown in 
Figure 3.2 was mainly due to the similar kcat of Phe-3-HPG and phenylalanine benzyl 
ester, despite the faster chemical hydrolysis of Phe-3-HPG. It may be an indication that at 
this point the deacylation rate is similar to acylation rate or even smaller, although it may 
also be a coincidence because lability is not the only factor determining k2. 
The leaving groups of hVACVase-catalyzed reactions are of interest because they 
correspond to the drug part of the prodrug molecule. The kinetic studies with a series of 
valine and phenylalanine analogues provided insight into the effect of leaving groups on 
hVACVase-catalysed hydrolysis. The comparison of kcat values between Val-3-HPG and 
Val-3-APG suggested that the acylation step was rate-limiting for the amine leaving 
group, which explains why amides are poor substrates of hVACVase.[8] In contrast to 
esters, amide prodrugs are more likely to circumvent hVACVase-catalyzed hydrolysis, 
which may be beneficial for prodrug targeting purposes. The different kcat values of 
valine and phenylalanine esters presented in this study suggested that the acylation step 
was also rate-limiting for most ester substrates, especially the ones with less labile 
leaving groups. Therefore, a good hVACVase substrate should have a leaving group 
labile enough for a reasonable activation rate, but not too liable to be chemically unstable.  
Assuming acylation as the rate-limiting step, the Km value should be the same as 




acid esters showed similarly high affinity to hVACVase except phenylalanine methyl and 
ethyl esters, probably because methyl and ethyl groups are too small to have favorable 
interactions such as hydrophobic interactions with the leaving group binding pocket. 
Despite the negative electrostatic potential in the leaving group-accommodating groove, 
Val-3-HPG and Phe-3-HPG with the positively charged leaving group exhibited similar 
binding affinity to valine and phenylalanine benzyl esters, respectively. This may be due 
to the water molecules in the leaving group-accommodating groove, which interfere with 
the proposed favorite electrostatic interaction. Although structurally similar to Val-3-
HPG, the amide Val-3-APG showed much lower affinity to hVACVase. The difference 
of ester and amide could be due to (1) the hydrogen bond[13, 14] between the amide 
hydrogen and the hydroxyl oxygen of S122 and (2) the unfavorable interaction between 
the amide hydrogen and the hydroxyl hydrogen of S122 (Scheme 3.4). 
In summary, the results suggested that the leaving groups of amino acid esters had 
an effect on both the binding and reaction rate of hVACVase-catalysed hydrolysis. 
However, the requirement for the leaving groups should be relatively flexible due to the 
large open leaving group-accommodating groove. Therefore, hVACVase may serve as an 
amino acid ester prodrug-activating enzyme target for a broad range of parent drugs with 
reasonable sizes and labilities. On the other hand, the amino acid amides are very poor 

















































































































Table 3.1. Estimated half-lives of valine analogues in pH 7.4 HEPES buffer (esters, mean 
± SEM, n=3; Val-3-APG, n=1). 
 
 Half-lives (min) 
Valine p-nitrobenzyl ester 412.3 ± 11.9 
Val-3-HPG 486.9 ± 6.6 
valacyclovir 742.1 ± 5.5 
Val-OBz 857.8 ± 7.6 








Table 3.2. Estimated half-lives of phenylalanine analogues in pH 7.4 HEPES buffer 
(mean ± SEM, n=3). 
 
 Half-lives (min) 
Phe-3-HPG 230.0 ± 6.5 
Phe-OBz 365.0 ± 9.4 
Phe-OMe 470.6 ± 12.6 






Table 3.3. Michaelis-Menten kinetic parameters of valine derivatives for hVACVase-
mediated hydrolysis (mean ± SEM; n=3). 
 












14 ± 1 272 ± 3 130 ± 2 9490 ± 580 
Val-3-HPG 46 ± 5 321 ± 9 154 ± 4 3370 ± 460 
valacyclovir 68 ± 4 120 ± 2 58 ± 1 850 ± 66 
Val-OBz 60 ± 15 125 ± 7 60 ± 3 992 ± 300 
Val-3-APG 1810 ± 80 




















Table 3.4. Michaelis-Menten kinetic parameters of phenylanine derivatives for 
hVACVase-mediated hydrolysis (mean ± SEM; Phe-OMe, n=2; others, n=3). 
 










Phe-3-HPG 207 ± 16 718 ± 16 345 ± 8 1660 ± 160 
Phe-OBz 99 ± 26 822 ± 54 395 ± 26 3980 ± 1310 
Phe-OMe 5140 ± 1120 474 ± 49 228 ± 24 44 ± 14 





Table 3.5 Kinetic parameters for N-acetyltryptophanyl substrates of chymotrypsin 
(adopted from reference [11]). 




-OEt 0.097 0.448 
-OMe 0.095 0.462 
-OPNP 0.002 0.508 






Figure 3.1. Correlation between the turnover number kcat of hVACVase-catalyzed 
































Figure 3.2. Correlation between the turnover number kcat of hVACVase-catalyzed 
hydrolysis and first order rate constant k of buffer hydrolysis for phenylalanine esters of 
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One of the dilemmas in drug development is that the most potent therapeutic 
agents may not have favorable biopharmaceutical properties, such as high oral 
absorption. Ironically sometimes the most important functional groups for the optimal 
binding to the drug target are actually the barriers for oral delivery. As an example, the 
positively charged guanidino group of anti-influenza agent zanamivir is not only essential 
for its high affinity to influenza neuraminidase, but also one of the reasons for its low oral 
bioavailability. The solution of this problem normally involves an analogue approach, 
screening for new compounds to balance the potency and biopharmaceutical properties. 
However, this approach may not always provide the required drug profile, especially 
when the drug binding pocket is hydrophilic. Another approach to improve oral 
absorption is the prodrug approach. Prodrugs are inactive drug analogues which can be 
metabolized to the active drug in vivo after the pharmaceutical, pharmacokinetic or 
pharmacodynamic barriers are overcome. The classic prodrug strategy is most commonly 
used to shield the charges and decrease the polarity of a poorly absorbed drug and 
facilitate passive diffusion following the usually non-specific biotransformation to the 
active parent drug. The transporter- and enzyme-targeted prodrug approach, however, is 
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aiming at targeting the prodrugs to membrane transporters and intracellular activating 
enzymes, which makes the prodrug design more rational and less empirical. 
The first specific aim of this research was to apply a transporter- and enzyme-
targeted prodrug approach to guanidino-containing drugs (Figure 4.1). Among the 
membrane transporters expressed in the brush border membrane of the small intestine 
that may tolerate the guanidino functionality, hPEPT1 is one of the most well-studied and 
widely used for prodrug targeting purposes. hPEPT1 mediates the intestinal absorption of 
di- and tripeptides including guanidino-containing arginine analogues as well as 
peptidomimetics. Despite its broad substrate specificity, the preference of hydrophobic 
side chains for hPEPT1 may be a problem for guanidino-containing parent drugs. 
Therefore, a model parent compound, [3-(hydroxymethyl)phenyl]guanidine (3-HPG), and 
its L-valine, L-isoleucine and L-phenylalanine esters were used to test the extent to which 
the guanidino group can be tolerated by hPEPT1. Although the amino acid ester 
hydrolysis can be catalyzed either chemically or by multiple esterases or proteases, a 
specific amino acid ester prodrug-activating enzyme hVACVase was chosen as the 
activation target to ensure the quick in vivo biotransformation .  
At first the buffer and enzymatic hydrolysis of 3-HPG and its amino acid esters 
were evaluated. The parent compound 3-HPG was very stable at all conditions, making it 
an excellent model parent compound. The amino acid esters exhibited relatively good 
stability in pH 6.0 and 7.4 buffers but much faster hydrolysis in HeLa and Caco-2 cell 
homogenates, which are the favorable properties for prodrugs. Then, the kinetic 
parameters of hVACVase-mediated hydrolysis were determined. All of the 3-HPG esters 
showed higher specificity constant (kcat/Km) than the reference substrate valacyclovir, 
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3370 for Val-3-HPG, 1580 for Ile-3-HPG, 1660 for Phe-3-HPG and 850 for 
valacyclovir). The [
3
H]Gly-Sar uptake inhibition was conducted to determine the affinity 
to hPEPT1. Both Val-3-HPG and Ile-3-HPG exhibited higher affinity than hPEPT1 
substrate valacyclovir (IC50 values: Val-3-HPG 0.65 mM, Ile-3-HPG 0.63 mM, 
valacyclovir 1.42 mM) and the comparison with corresponding benzyl ester suggested 
that the guanidino functionality did not hinder the binding to hPEPT1 transporter. In the 
direct uptake studies, all the three L-amino acid esters showed higher uptake (2.6- to 9-
fold) than the parent compound 3-HPG in HeLa/hPEPT1 cells. Compared with normal 
HeLa cells, the 3-HPG esters displayed 8- to more than 25-fold increased uptake, 
whereas 3-HPG only showed little enhancement. It suggested that the L-amino acid 3-
HPG esters were not only inhibitors of hPEPT1 but also substrates. In Caco-2 cells, Val-
3-HPG and Ile-3-HPG demonstrated remarkable permeability enhancement and Val-3-
HPG exhibited comparable permeability to valacyclovir. The low permeability of D-Val-
3-HPG indicated that Val-3-HPG transport was carrier-mediated and the studies with 
inhibitors suggested that hPEPT1 was the predominant transporter. In rat perfusion 
studies, Val-3-HPG and Ile-3-HPG permeabilities were significantly higher than 3-HPG 
and also exceeded/matched the high-permeability standard metoprolol, respectively. 
Combined with the subsequent prodrug studies with the guanidino-containing parent 
compounds zanamivir and GOCarb, the results indicated that the prodrug strategy is 
effective at increasing the intestinal permeability of polar guanidino analogues via 
targeting hPEPT1 for transport and hVACVase for activation.  
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The second specific aim was to investigate the effect of leavings group on the 
hVACVase-catalyzed prodrug activation. hVACVase is a serine hydrolase specific for 
the hydrolysis of α-amino acid esters. The broad leaving group-accomodating groove 
makes it a potentially universal prodrug-activating target for amino acid analogues. To 
determine the effect of leaving groups on the binding affinity and specific activity, the 
kinetic studies of a series of valine esters (Val-3-HPG, valacyclovir, valine benzyl ester, 
valine p-nitrobenzyl ester), phenylalanine esters (Phe-3-HPG, phenylalanine benzyl ester, 
phenylalanine ethyl ester, phenylalanine methyl ester) and a valine amide Val-3-APG 
were conducted.  
Compared with Val-3-HPG, the amide Val-3-APG exhibited more than four 
orders of magnitude lower kcat value, which clearly indicated that the acylation step was 
rate-limiting. Combined with the high Km value, the specificity constant (kcat/Km) of Val-
3-APG was negligible. This is consistent with the previous result that hVACVase cannot 
activate amides. Therefore, amide prodrugs are more likely to circumvent the 
ubiquitously expressed hVACVase, which may be beneficial for prodrug-targeting 
purposes. For the amino acid esters, the correlation between the kcat values of 
hVACVase-catalyzed hydrolysis and the first order rate constant k of buffer hydrolysis 
suggested that the acylation step may still be rate-limiting for some of the labile primary 
alcohol leaving groups. Therefore, a good hVACVase substrate should have a leaving 
group labile enough for a reasonable activation rate, but not too liable to be chemically 
unstable. The leaving groups seem to affect binding to hVACVase as well, although the 
favorable features for binding need to be further identified. However, with the broad 
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leaving group-accommodating groove, the requirement for the leaving group binding 
should not be stringent.  
In conclusion, the transporter- and enzyme-targeted approach is successful to 
enhance the oral absorption of a guanidino-containing model compound, indicating its 
feasibility for other poorly-absorbed guanidino analogs. The results in this study 
suggested that the leaving groups had an effect on both the binding and specific activity 
of hVACVase-catalyzed prodrug activation, and the high specificity constant (kcat/Km) of 
3-HPG esters presumably resulted from high binding affinity to hVACVase as well as 
favorable lability of the leaving group. hVACVase is an ideal target for activating α-
amino acid ester prodrugs with relatively labile leaving groups but is unable to activate 









Figure 4.1. The transporter- and enzyme-targeted approach.  
 
 
